Thromboxane Receptor Antagonists in AERD/Asthma
AssigneeCumberland Pharmaceuticals Inc.
InventorLeo Pavliv
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.
Claims19
A method of treating and/or preventing AERD or asthma in human patients, comprising administering to a human patient ifetroban or a pharmaceutically acceptable salt thereof in a daily dose from about 25 mg to about 400 mg.
A method of preventing, reversing or treating a symptom(s) of aspirin desensitization in AERD patients, comprising administering ifetroban or a pharmaceutically acceptable salt thereof to a human suffering from AERD in a daily dose from about 25 mg to about 400 mg.
A method of reducing rescue medications needed as a result of an aspirin-induced reaction in a human patient(s) suffering from AERD, comprising comprising administering ifetroban or a pharmaceutically acceptable salt thereof to the patient(s) in a daily dose from about 25 mg to about 400 mg.
Dependencies are inferred from the claim text.